12.12.2024

The Medical Research Agency (ABM) has just announced its plan for 2025 (ABM plan-dzialalnosci/2025/2929). In its Activity Plan for 2025, it identifies key areas that respond to the contemporary challenges of medicine and healthcare. We are proud to emphasize that our existing projects and innovative technologies precisely support the implementation of these ambitious goals, contributing to the improvement of healthcare quality in Poland.

ABM plans to analyze the impact of the widespread use of continuous glucose monitoring (CGM) devices on the effectiveness of diabetes treatment.

Proacta is already ahead of these initiatives, offering pilot models of CGM systems that are being successfully tested in hospitals. Our solutions enable detailed analysis of CGM data, which supports better treatment adjustment and improves patients' quality of life.

The ABM open competition for research experiments provides for the development of new medical procedures and the optimization of patient pathways across a wide range of conditions, including cardiovascular, neurological, autoimmune, and cancerous diseases.

Proacta has extensive experience in analyzing data related to medical procedures. Our analytical tools allow for an in-depth assessment of the effectiveness of diagnostic and therapeutic procedures, making us a natural partner for initiatives of this type.

The ABM plan includes launching a competition for clinical trials aimed at identifying and evaluating new therapeutic indications for medicinal products. The goal of these trials is to develop new standards of treatment, diagnosis, or rehabilitation for chronic, autoimmune, and cancerous diseases.

Proacta already offers products that redefine treatment and diagnostic standards. Our solutions are based on the latest clinical research, which is in line with ABM's mission in Poland.